Clin2
NCT07660614Likely a fitRecruiting

Testing a new drug for people with ALS

Amyotrophic Lateral Sclerosis

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
56 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have been diagnosed with ALS using the Gold Coast criteria.
  • Your first ALS symptoms started less than 3 years ago.
  • Your breathing test (slow vital capacity) is at least 50% of normal for your age and height.
  • Your body mass index (BMI) is between 18 and 40.
  • You have not had a tracheostomy or a previous treatment with certain gene-targeting therapies.
  • You are not pregnant or breastfeeding and have no bleeding problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06513546Not yet recruiting· Phase 1/Phase 2
Testing a new drug (PLL001) for early-stage ALS

This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.

NCT06726577Recruiting· Phase 1/Phase 2
A new drug for ALS: phase 1/2 safety and effectiveness trial

This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.

Suzhou, Jiangsu
NCT07287397Recruiting· Phase 1/Phase 2
Testing VTx-002 for safety in ALS patients

This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.

Phoenix, Arizona
NCT07571174Recruiting· Phase 1
ALS Study: Testing a New Drug in Spinal Fluid

This is a follow-up study for people with ALS (a disease affecting nerve and muscle control) who completed a previous trial called OWAA. Researchers want to test how a new experimental drug called LY4256984 affects the spinal fluid around your brain and spine, which may help them understand if it could slow disease progression.

Leuven
NCT07674667Recruiting· Phase 1/Phase 2
Testing a treatment to restore UNC13A function in ALS

This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.

Munich
NCT07325591Not yet recruiting· Phase 2/Phase 3
Testing tazbentetol for ALS safety and effectiveness

This trial tests whether a drug called tazbentetol can help people with ALS. It aims to see if it is safe and slows the disease's progression.

Hear when a new Amyotrophic Lateral Sclerosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.